Evidence map›Paper›PMID 35321690›Full record

Trial reportBMC cancer2022

Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis.

Senri Yamamoto, Hirotoshi Iihara, Ryuji Uozumi, Hitoshi Kawazoe, Kazuki Tanaka, Yukiyoshi Fujita, Masakazu Abe, Hisao Imai, Masato Karayama, Yoh Hayasaki and 7 more

Open access · goldAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. MASCC antiemetic consensus recommendations: resource-limited settings.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 1 country.

Senri YamamotoDepartment of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.
Hirotoshi IiharaDepartment of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan. dai0920@gifu-u.ac.jp.
Ryuji UozumiDepartment of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Hitoshi KawazoeDivision of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, Tokyo, 105-8512, Japan.
Kazuki TanakaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan.
Yukiyoshi FujitaDivision of Pharmacy, Gunma Prefectural Cancer Center, 617-1 Takahayashi-nishi, Ohta, Gunma, 373-8550, Japan.
Masakazu AbeDivision of Gynecology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Hisao ImaiDivision of Respiratory Medicine, Gunma Prefectural Cancer Center, 617-1, Takahayashi-nishi, Ohta, Gunma, 373-8550, Japan.
Masato KarayamaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan.
Yoh HayasakiDepartment of Obstetrics and Gynecology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
Chiemi HiroseDepartment of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.
Takafumi SudaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan.
Kazuto NakamuraDepartment of Gynecology, Gunma Prefectural Cancer Center, 617-1 Takahayashi-nishi, Ohta, Gunma, 373-8550, Japan.
Akio SuzukiDepartment of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.
Yasushi OhnoDepartment of Cardiology and Respiratory Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
Ken-Ichirou MorishigeDepartment of Obstetrics and Gynecology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
Naoki InuiSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka, 431-3192, Japan. inui@hama-med.ac.jp.
Gifu University Hospital · JPHamamatsu University School of Medicine · JPGifu University · JPGunma Children's Medical Center · JPKeio University · JPKyoto University · JPSaitama Medical University · JPShizuoka Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOlanzapine has been reported to be an effective antiemetic in patients receiving carboplatin-based chemotherapy. However, the efficacy of a neurokinin-1 receptor antagonist (NK

methodsData were pooled for 140 patients receiving carboplatin-based chemotherapy from three multicenter, prospective, single-arm, open-label phase II studies that evaluated the efficacy and safety of olanzapine for chemotherapy-induced nausea and vomiting. The propensity score of the co-administration of NK

resultsThe complete response rate (without emetic episodes or with no administration of rescue medication) in the overall period (0-120 h post carboplatin administration) was 93.5% in the non-NK

conclusionsThe findings suggest that antiemetic regimens consisting of olanzapine, 5HT

Indexed as

CarboplatinNauseaNeurokinin-1 Receptor AntagonistsSerotonin 5-HT3 Receptor AntagonistsVomitingDexamethasoneHumansOlanzapinePropensity ScoreProspective StudiesCarboplatinDexamethasoneNeurokinin-1 Receptor AntagonistsOlanzapineSerotonin 5-HT3 Receptor Antagonists5-hydroxytryptamine-3 receptor antagonistsAntiemeticsCarboplatinDexamethasoneNauseaNeurokinin-1 receptor antagonistOlanzapineVomiting

Identifiers

PMID35321690
PMCPMC8941806
OpenAlexW4220671740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.